Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 6/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.35 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5038916 | 0.96 | LSS (0.46) | LSSP2RY14FFAR4FAAHHDAC1 | |
| SCHEMBL5043354 | 0.87 | LSS (0.42) | LSSTRPV1 | |
| SCHEMBL5035373 | 0.86 | LSS (0.45) | LSS | |
| SCHEMBL7171097 | 0.86 | LSS (0.41) | LSSP2RY14FFAR4FAAHMKNK1 | |
| SCHEMBL5045284 | 0.86 | LSS (0.41) | LSSFFAR4 | |
| SCHEMBL5038995 | 0.85 | LSS (0.55) | LSSTRPV1 | |
| SCHEMBL7152759 | 0.85 | LSS (0.42) | LSSFFAR4MKNK1MKNK2MAOB | |
| SCHEMBL5038928 | 0.85 | LSS (0.43) | LSS | |
| SCHEMBL5038232 | 0.84 | LSS (0.54) | LSSTRPV1 | |
| SCHEMBL5039610 | 0.84 | LSS (0.64) | LSSMAPK1PDE3BPDE3AP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7449483-B2 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. (US) | 2008-11-11 | — | — | US | disclosed |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | AEBI JOHANNES | 2007-05-03 | — | — | US | disclosed |
| US-7173043-B2 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | AEBI JOHANNES | 2005-12-01 | — | — | US | disclosed |
| US-6951879-B2 | Substituted benzo(b)thiophenes or benzoisothiazoles which inhibit 2,3-oxidosqualene-lanosterol cyclase which is required for the biosynthesis of cholesterol, ergosterol and other sterols | HOFFMANN-LA ROCHE INC. (US) | 2005-10-04 | — | — | US | disclosed |
| EP-1334094-B1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2004-12-29 | — | — | EP | disclosed |
| EP-1334094-A1 | CHOLESTEROL LOWERING BENZO[B]THIOPHENES AND BENZO[D]ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-13 | — | — | EP | disclosed |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | HOFFMAN-LA ROCHE INC. | 2002-07-04 | — | — | US | disclosed |
| WO-2002036584-A1 | CHOLESTEROL LOWERING BENZO`B! THIOPHENES AND BENZO`D! ISOTHIAZOLES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267200-A1 | Enzyme inhibitors for cyclases as anticholesterol agents or cardiovascular disorders | LSS, CYP51A1, CYP46A1 | LSS 1/4885P2RY14 3752/4885FFAR4 3476/4885 |
| US-20070099985-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | LSS 1/4885P2RY14 4059/4885FFAR4 2638/4885 |
| US-20020086891-A1 | Heteroaromate OSC inhibitors | LSS, CYP51A1, CYP46A1 | LSS 1/4885P2RY14 4059/4885FFAR4 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.